SCHEMBL19950139

SCHEMBL19950139

N#CCc1cccc(F)c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
GPR84 Q9NQS5 2/20 0.35
CSNK2A1 P68400 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
FFAR1 O14842 3/20 0.33
FFAR4 Q5NUL3 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
GRIA1 P42261 1/20 0.33
CACNG8 Q8WXS5 1/20 0.33
TSPO P30536 1/20 0.33
DRD3 P35462 1/20 0.33
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30070555 1.00 HPGD (0.38) HPGDALDH1A1GABRA1GABRB2GPR84
SCHEMBL13278320 0.85 GABRA1 (0.48) HPGDALDH1A1GABRA1GABRB2CSNK2A1
SCHEMBL837981 0.79 HPGD (0.40) HPGDALDH1A1MEN1MAPTKMT2A
SCHEMBL29893592 0.79 HPGD (0.40) HPGDALDH1A1MEN1MAPTKMT2A
SCHEMBL6333464 0.79 CYP1A1 (0.40) HPGDALDH1A1GABRA1GABRB2CSNK2A1
SCHEMBL29734785 0.79 TAAR1 (0.48) HPGDALDH1A1MEN1MAPTKMT2A
SCHEMBL103401 0.79 TAAR1 (0.48) HPGDALDH1A1MEN1MAPTKMT2A
SCHEMBL25328810 0.78 CSNK2A1 (0.35) HPGDALDH1A1GPR84CSNK2A1FFAR1
SCHEMBL31454483 0.76 HPGD (0.38) HPGDALDH1A1MEN1MAPTKMT2A
SCHEMBL11919558 0.76 ALDH1A1 (0.38) HPGDALDH1A1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 US disclosed
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-08-29 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
CN-115819417-A Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2023-03-21 CN disclosed
CN-113087700-B Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2023-03-14 CN disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-4101852-A1 PYRIDOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF Bebetter Med Inc. (CN) 2022-12-14 EP disclosed
CN-109923114-A Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2019-06-21 CN disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 HPGD 118/4885ALDH1A1 2205/4885GABRA1 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.